https://www.selleckchem.com/products/mycmi-6.html
BACKGROUND Dasotraline is a long-acting dopamine/norepinephrine reuptake inhibitor with a PK profile characterized by slow absorption and a t½ of 47-77 hours, permitting once-daily dosing. In a previous flexible dose study, dasotraline demonstrated significant efficacy in the treatment of binge-eating disorder (BED). The aim of this confirmatory fixed-dose study was to evaluate efficacy and safety of dasotraline in the treatment of patients with BED. METHODS Patients meeting DSM-5 criteria for BED were randomized to 12 weeks of double-b
Like
Comment
Share
